MindMed Corporate Over April 2022 Disclaimer This presentation (the Presentation ) has been prepared by Mind Medicine (MindMed) Inc. ( MindMed or the Company ) solely for informational purposes. None of MindMed, its affi

MindMed Corporate Over April 2022

Disclaimer This presentation (the Presentation ) has been prepared by Mind Medicine (MindMed) Inc.

( MindMed or the Company ) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representatives or agents

makes any representation or warranty as to the accuracy or completeness of any information contained in this Presentation and shall have no liability for any representations (expressed or implied) contained in, or for any omissions from, this

Presentation. This presentation shall not constitute an offer, nor a solicitation of an offer, of the sale or purchase of securities. This Presentation does not constitute an offering of securities of MindMed and under no circumstances is it to be

construed as a prospectus or advertisement or public offering of securities. Any trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the

products or services of MindMed. Any amounts are in USD unless otherwise noted. MindMed s securities have not been approved or disapproved by the SEC or by any state, provincial or other securities regulatory authority, nor has the SEC or any

state, provincial or other securities regulatory authority passed on the accuracy or adequacy of this Presentation. Any representation to the contrary is a criminal offense. Cautionary Note Regarding Forward-Looking Statements This Presentation

contains, and our officers and representatives may from time to time make, forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable

securities laws. Forward- looking statements can often, but not always, be identified by words such as plans , expects , is expected , budget , scheduled , estimates ,

forecasts , intends , anticipates , will , projects , or believes or variations (including negative variations) of such words and phrases, or statements that certain actions, events,

results or conditions may , could , would , might or will be taken, occur or be achieved, and similar references to future periods. Except for statements of historical fact, examples of

forward-looking statements include, among others, statements pertaining to the development and commercialization of any medicine or treatment, or the efficacy of either of the foregoing, the success and timing of our development activities, the

success and timing of our planned clinical trials, our ability to meet the milestones set forth herein; the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approvals, the likelihood of obtaining patents or the

efficacy of such patents once granted, and the potential for the markets that MindMed is anticipating to access. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our

current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions as of the date of this Presentation. While we

consider these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties that are difficult to predict and many of which are

outside of our control, and our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that

could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to raise capital to complete its plans and fund its studies; the

medical and commercial viability of the contemplated medicines and treatments being developed; our ability to raise additional capital in the future as we continue to develop our products; our history of negative cash flows; our limited operating

history; incurrence of future losses; availability of additional capital; lack of revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened

regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to throughout the Risk

Factors sections of our most recently filed Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC ) and in other filings we make in the future with the SEC and

the securities regulatory authorities in all provinces and territories of Canada, available under the Company s profile on SEDAR at www.sedar.com. Any forward-looking statement made by us in this Presentation is based only on information

currently available to us and speaks only as of the date on which it is made. MindMed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new

information, future developments or otherwise. Cautionary Note Regarding Regulatory Matters The United States federal government regulates drugs through the Controlled Substances Act. The Company works with a

non-hallucinogenic synthetic derivative of the psychedelic substance ibogaine, known as 18-MC , which is a synthetic organic molecule designed around a common

coronaridine chemical backbone. 18-MC is not a Schedule I substance in the United States and the Company does not foresee it becoming a Schedule I substance due to its

non-hallucinogenic properties. While the Company is focused on programs using psychedelic inspired compounds and classic psychedelics, the Company does not have any direct or indirect involvement with the

illegal selling, production or distribution of any substances in the jurisdictions in which it operates. The Company is a neuro-pharmaceutical drug development company and does not deal with psychedelic substances except within laboratory and

clinical trial settings conducted within approved regulatory frameworks. The Company s products will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the

intended uses is successfully developed.] Market and Industry Data This Presentation by includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is

accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources

believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third party sources referred to

in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of

the entire referenced report or article. MindMed does not make any representation as to the accuracy of such information. MindMed Corporate Overview | April 2022 2

Business Highlights Our mission is to deliuer on the therapeutic potential of psychedelics and other nouel

targets to treat brain health disorders Leader in developing psychedelic product candidates to treat brain health disorders Diversified pipeline of clinical programs targeting significant unmet medical needs IP and R&D

strategies to maximize market exclusivity and protection Leveraging decades of research on clinical and preclinical potential of product candidates Industry-leading expertise in drug and digital medicine development and

commercialization Fully funded through key clinical readouts and into 2024 MindMed Corporate Overview | April 2022 3

There is an Urgent Need for Better Treatments Substantial opportunities exist to advance novel treatments for a

wide range of brain health disorders >- J 1-year prevalence of anxiety 7 | /O disorders in the US2 W W W W 15 0 M Q people in

the US overdosed W W W W Ww Q on opioids in 2020 1 in 5 U.S. Adults is Diagnosed with a Mental Health Disorder . Q A economic cost of ASD in the < I Ev US predicted by 2O255 1. Mental Illness 2020; NIMH 2. Bandelow 2015; Dialogues Clin. Neurosci;

17(3) 3. Zelaya 2019; NCHS Data Brief. 2020;(390) 4. Overdose Death Rates 2022, February 1; NIDA 5. Leigh & Du 2015; J. Autism Dev. Disord. 45(12) MindMed Corporate Overview | April 2022 4

Advancing Multiple Generations of Drug Candidates Our strategy is to deliver on well-characterized psychedelic

candidates and next generation candidates with enhanced drug profiles 1 o Expanded clinical indications Clinical evidence of efficacy /H3 * N N CLASSIC HC Psychedelics with distinct PK/PD PSYCHEDELICS

Well-characterized pharmacology Accelerated development potential MM-120 i I Universitatsspital DMT Mescaline 83561 Enhanced pharmacology Advanced drug delivery

OPTIM ZEEDATI N/ Overcome safety liabilities Novel treatment models Increased IP potential 3 Novel treatment regimen MM-402 0CH3 Novel tryptamines Analogues

of classic psychedelics NCES ENERAT, N/ Recluire ful1 development program oAicnj Novel Phenethylamines Strongest IP potential MM-HO

Non-hallucinogenic analogues 1. Gasser 2014; J. Nerv. Merit. Dis.; 202(7). IP: intellectual property; DMT: N,N-dimethyltryptamine; NCE: new chemical entity; PD: pharmacodynamics; PK: pharmacokinetics MindMed

Corporate Overview | April 2022 5

Research & Development Pipeline Our pipeline diversification offers potential opportunities across

therapeutic areas and mechanisms of action PSYCHIATRY ADHD MM-402 (R(-)-MDMA) Autism Spectrum Disorder SUBSTANCE USE DISORDERS MM-110 (zolunicant HCI) Opioid Withdrawal

PAIN DISCOVERY & EARLY DEVELOPMENT MM-823 (noribogaine BTLS) Substance Use Disorders Novel tryptamines undisclosed Novel phenethylamines undisclosed Advanced drug delivery undisclosed ADHD:

Attention-Deficit/Hyperactivity Disorder MindMed Corporate Overview | April 2022 6

Upcoming Portfolio Milestones MindMed s clinical research portfolio creates multiple near-term and

intermediate catalysts PSYCHIATRY MM-120 (LSD D-tartrate) Generalized Anxiety Disorder S ADHD MM-402

(R(-)-MDMA) Autism Spectrum Disorder SUBSTANCE USE DISORDERS / HWWWWIk MM-110 (zolunicant HCI) Opioid Withdrawal PAIN MM-120 (LSD D-tartrate) Chronic Pain ADHD: Attention-Deficit/Hyperactivity Disorder; IIT: investigator-initiated trial; R&D: research & development; ESOE: early sign of efficacy MindMed Corporate Overview | April

Advancing the Field with Strong IP & Strategic Competitive Moats Our approach is to protecting

innovation and market potential through intellectual property-oriented R&D strategies Strategic Life Cycle Management & Late-Stage IP for Innovation Development Can Significantly Extend Market Protection & Strong IP / FDA-granted NCE I I exclusivity Proactive Lifecycle Market Protection Extended market protection | _ \ k with superior LCM Market exclusivity based I IP-Driven on

late-development IP* | R&D Direction X. s YEARS OF MARKET PROTECTION *For illustrative purposes only R&D: Research & Development; LCM: Life Cycle Management MindMed Corporate Overview | April 2022 8

LSD-Anxiety Topline Readout Q2 2022 | Phase 2 (IIT) GAD First Patient

Dosing >1 I 2022 phase Chronic Pain Study Initiation Q4 2022 | Phase 2 ESOE MindMed Corporate Overview | April 2022 9

MM-120 | Lead Candidate with Evidence Across Multiple Therapeutic Areas

Extensive evidence of clinical benefit and mechanistic rationale in psychiatry, pain and substance use disorders 1 Rapid & sustained 3x Effect Size benefit after acute dosing1 compared to available affective disorder therapies2 Novel MOA

2nd Generation that targets neurobiology of delivery opportunity to enhance access 10,000+ Well characterized SAFETY & PHARMACOLOGY patients treated in tolerability, pharmacokinetics clinical trials1 and pharmacodynamics 1. Gasser 2014; J.

Nerv. Ment. Dis.; 202(7). 2. Fuentes 2020; Front Psychiatry; 10:943. MOA: mechanism of action MindMed Corporate Overview | April 2022 10

MM-120 | Emerging Treatment Paradigm for Brain Health Disorders Novel

mechanisms of action with transdiagnostic applicability Global Brain Connectivity / Placebo (Low Entropy) Psychedelic drug (High Entropy) I Increased

single neuron excitability Layer V v-fj & Psychedelic pyramidal A drug delivered neuron > t _| 5 mV 2.0 1.5 1.0 0.5 0.0 Source: Nutt 2020. Cell; 181(1). Enrichment of

5-HT2A Expression MindMed Corporate Overview | April 2022 11

MM-120 | Legacy of LSD Clinical Research in Psychiatric Disorders

Building on decades of clinical research on LSD in anxiety and depression 21 STUDIES Anxiety, depression & 512 patients Up to 95% reduction in PRIOR T019741 neuroses symptoms GASSER 20142 Anxiety in 12 patients Effect size of

1.1 with durable terminal illness reductions in anxiety at 1 year LSD-ASSIST STUDY Anxiety 41 patients Topline results expected in Q2 2022 Rucker Gasser MindMed Corporate Overview | April 2022 12

MM-120 | Phase 2b Generalized Anxiety Disorder (GAD) Study design seeks

to demonstrate dose-responsive effects and identify optimal dose for pivotal clinical trials PSYCHIATRY MM-120 (LSD D-tartrate) Indication: GAD 200 participants total

(n=40/arm) HMHM M H B Phase Dose Week | J | B B 1 B B Study a Dose of MM-120 in Generalized Anxiety Disorder Prep Dose

Follow-Up I MM-120 200 pg Secondary Endpoint KEY ENTRY CRITER,A I MM-120 100 pg HAM-A .

j en anc| Women Ages 18-74 I MM-120 50 pg * Diagnosis of GAD HAM-A >20 |

MM-120 25 pg Placebo ADDITIONAL ENDPOINTS MADRS EQ-5D-5L CGI-S/I

PSQI Randomize Primary Endpoint PGI-S / C ASEX HAM-A . SDS Source: MindMed internal study documents pg: microgram; HAM-A: Hamilton Anxiety Rating

Scale; MADRS: Montgomery-Asberg Depression Rating Scale; CGI-S: Clinical Global Impression Severity; PGI-S: Patient Global Impression Severity; SDS: Sheehan

Disability Scale; EQ-5D-5L: EuroQol-5 Dimension; PSQI: Pittsburgh Sleep Quality Index; ASEX: Arizona Sexual Experiences Scale

MindMed Corporate Overview | April 2022 13

MM-120 | Phase 2a Attention Deficit Disorder (ADHD) Proof of concept

study design seeks to explore potential clinical response in ADHD PSYCHIATRY MM-120 (LSD D-tartrate) Indication: ADHD 52 participants total (n=26/arm) A Phase 2a Proof

of Concept Study Week LOW OSES for the Treatment of ADHD in Adults Prep Dosing Follow-Up KEY ENTRY CRITERIA Secondary Endpoint . Men and Women Ages Diagnosis of ADHD AISRS >

26 CGI-S > 4 ADDITIONAL ENDPOINTS AISRS @ 1 week Randomize Primary Endpoint CGI-S AISRS ASRS CAARS Sleep Diary Source:

MindMed internal study documents AISRS: Adult ADHD Investigator Symptom Rating Scale; ASRS: Adult ADHD Self-Report Scale; CAAR: Conners Adult ADHD Rating Scales; CGI-S: Clinical Global

Impression Severity MindMed Corporate Overview | April 2022 14

MM-120 | Novel Applications in Chronic Pain Preclinical and early

clinical evidence provide support for unique mechanism of action and potential clinical activity KAST 1967 Terminal cancer pain 128 patients 100 ug reduced cumulative pain scores for at least 12 hours post-treatment 2 FANCIULLACCI 1977 Phantom limb

pain 7 patients 50 pg (qd) reduced pain in 5 of 7 patients (full analgesia in 2 of 7) RAMAEKERS 2O213 Experimental pain in 24 patients 20 pg increased pain tolerance and healthy volunteers reduced cold pressor test painfulness i Study Design To be

announced Dosing Regimen Repeat administration Indication Chronic Pain 1. Kast 1967. Psych Quar 41,646-657. Primary Endpoint Change in Daily Pain on 11-point Numerical

Rating Scale 2. Fanciullacci 1977. The Journal of Head and Face Pain, 17:118-119. 3. Ramaekers 2021. Journal of Psychopharmacology; 35(4). MindMed Corporate Overview | April 2022 15

Phase 1 Topline Data Readout Q2 2022 | Phase 1 Opioid W/D Study Initiation Q2 2022 | Phase 2a Opioid W/D ESOE

Readout Q4 2022 | Phase 2a (Part A) MindMed Corporate Overview | April 2022 16

MM-110 | Novel Mechanism to Address a Critical Gap in OUD Treatment

Mechanism of action and target product profile complement standard-of-care and address a critical gap in available treatment landscape Opioid Initiation Opioid Use

Disorder MM-110-facilitated Medication Assisted Therapies (MAT) Superuised Withdrawal Dopamine regulation facilitates Long-term success through completion of detoxification & successful transition to